In last trading session, Travere Therapeutics Inc (NASDAQ:TVTX) saw 1.32 million shares changing hands with its beta currently measuring 0.76. Company’s recent per share price level of $23.58 trading at $0.25 or 1.07% at ring of the bell on the day assigns it a market valuation of $2.05B. That closing price of TVTX’s stock is at a discount of -7.25% from its 52-week high price of $25.29 and is indicating a premium of 78.29% from its 52-week low price of $5.12.

For Travere Therapeutics Inc (TVTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 8 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.38 in the current quarter.

Travere Therapeutics Inc (NASDAQ:TVTX) trade information

Upright in the green during last session for gaining 1.07%, in the last five days TVTX remained trading in the green while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $23.58 price level, adding 2.32% to its value on the day. Travere Therapeutics Inc’s shares saw a change of 35.36% in year-to-date performance and have moved 1.64% in past 5-day. Travere Therapeutics Inc (NASDAQ:TVTX) showed a performance of 21.17% in past 30-days.

Wall Street analysts have assigned a consensus price target of 21.5 to the stock, which implies a fall of -9.67% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 33. It follows that stock’s current price would jump 49.11% in reaching the projected high whereas dropping to the targeted low would mean a gain of 49.11% for stock’s current value.

Travere Therapeutics Inc (TVTX) estimates and forecasts

This year revenue growth is estimated to rise 59.14% from the last financial year’s standing.

15 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 72.38M for the same. And 9 analysts are in estimates of company making revenue of 72.68M in the next quarter. Company posted 45.06M and 41.37M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -12.34% during past 5 years.

Travere Therapeutics Inc (NASDAQ:TVTX)’s Major holders

BLACKROCK INC. is the top institutional holder at TVTX for having 7.64 million shares of worth $62.84 million. And as of 2024-06-30, it was holding 9.8642 of the company’s outstanding shares.

The second largest institutional holder is ARMISTICE CAPITAL, LLC, which was holding about 7.5 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6774 of outstanding shares, having a total worth of $61.65 million.

On the other hand, Delaware Group Equity Fds V-Small Cap Core Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 3.45 shares of worth $81.4 million or 4.42% of the total outstanding shares. The later fund manager was in possession of 2.51 shares on Sep 30, 2024 , making its stake of worth around $59.07 million in the company or a holder of 3.21% of company’s stock.